论文部分内容阅读
目的:评价人血丙种球蛋白(IVIG)和地塞米松对小儿重症肺炎患者的疗效及其对炎症指标的影响。方法:选取2014年1月—2016年12月间收治的小儿重症肺炎患者168例,采用随机分组法将其分为对照组和治疗组,每组84例;对照组患者在抗感染治疗基础上加用地塞米松治疗,治疗组患者对照组患者基础上加用IVIG治疗,比较两组患者用药后的总有效率及其对炎症指标的影响。结果:治疗组用药后的总有效率为95.24%高于对照组为76.19%(P<0.05);治疗组患者临床治疗后,各项观察指标均明显改善,且显著优于对照组(P<0.05)。结论:人血丙种球蛋白(IVIG)和地塞米松用于治疗小儿重症肺炎患者,有助于肺部功能的改善和临床症状的缓解。
Objective: To evaluate the effect of intravenous administration of IVIG and dexamethasone on children with severe pneumonia and its effect on inflammation. Methods: A total of 168 pediatric patients with severe pneumonia admitted from January 2014 to December 2016 were selected and randomly divided into control group and treatment group, with 84 cases in each group. On the basis of anti-infective treatment Plus dexamethasone treatment, the treatment group patients in the control group based on the addition of IVIG treatment, the total effective rate of two groups of patients after treatment and compared the impact of inflammation indicators. Results: After treatment, the total effective rate of the treatment group was 95.24%, which was significantly higher than that of the control group (76.19%, P <0.05). After the clinical treatment, the observation indexes of the treatment group were significantly improved, and were significantly better than the control group (P < 0.05). CONCLUSIONS: Human blood gamma globulin (IVIG) and dexamethasone are used to treat children with severe pneumonia and to improve pulmonary function and clinical symptoms.